A Safety Study of Combination Treatment With Avonex and Placebo-Contro
A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis.
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Interferon beta-1a
Interferon alpha/beta receptor agonist
What it measured
Main measures
Safety and tolerability
Safety
Other measures (3)
Brain atrophy on nMRI
Brain volume lossDisease progression on EDSS and MSFC
Disability progressionRelapse rate
Relapses
Who could take part
Relapsing MS · 18 to 55
Show the full criteria
Inclusion criteria
Relapsing-remitting multiple sclerosis -
Exclusion criteria
Secondary progressive multiple sclerosis Contraindication to MRI Systemic disease Pregnancy -
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax added to Avonex has a neuroprotective effect as measured by the brain parenchymal fraction ( a measure of brain shrinkage) and by clinical assessment scores to evaluate disease progression.
Papers
Loading reviews and guidelines…
Related trials
- Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting
Phase 3 · Not yet recruiting
Still running
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Recruiting
Still running
- Discontinuation of first-line disease modifying treatment (DMT) in lon
Phase 4 · Stopped early
Stopped
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY
Running, not recruiting
Still running
- Study to Investigate Pregnancy Outcomes in Female Participants Exposed
Completed
Paper found, not read
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017
Phase 3 · Running, not recruiting
Still running
History
Started
Apr 2004
Finished
Dec 2007